Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

Pubmed-Investigación

Front Pharmacol. 2021 Oct 7;12:718281. doi: 10.3389/fphar.2021.718281. eCollection 2021. ABSTRACT Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). Despite being more effective than monotherapies, they produce frequent adverse drug reactions (ADRs). Institutions such as Food and Drug Administration and European Medicines Agency recommend precaution with…

ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics

Pubmed-Investigación

Biomed Pharmacother. 2021 Oct;142:112083. doi: 10.1016/j.biopha.2021.112083. Epub 2021 Aug 24. ABSTRACT Eslicarbazepine acetate is a third-generation anti-epileptic prodrug quickly and extensively transformed to eslicarbazepine after oral administration. Reduction in seizure frequency in patients managed with eslicarbazepine is only partial in the majority of patients and many of them suffer considerable ADRs that require a change…